Literature DB >> 16020977

Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advanced gastric carcinoma.

Kenichi Yamaguchi1, Hiroaki Saito, Shotaro Oro, Shigeru Tatebe, Masahide Ikeguchi, Shunichi Tsujitani.   

Abstract

OBJECTIVE: Nitric oxide (NO) is a product of L-arginine to L-citrulline conversion by nitric oxide synthase (NOS). The inducible form of NOS (iNOS) is one of three classes of NOS and the strongest producer of NO. It has been reported that NO correlates with angiogenesis and immune responses in some types of cancer, however, the correlations between iNOS expression, angiogenesis, and immune responses are still unclear in gastric carcinoma.
METHODS: iNOS expression was determined in 135 gastric cancer patients by immunohistochemical procedures and compared with the expression of vascular endothelial growth factor (VEGF), microvessel (MV) density, and dendritic cell (DC) infiltration to evaluate the effect of iNOS on angiogenesis and immune responses in gastric carcinoma.
RESULTS: iNOS expression was detected in 106 (78.5%) of 135 cases. There was a close correlation between iNOS expression and VEGF expression, a correlation with MV density and an inverse correlation with DC infiltration. There was no correlation between iNOS and p53 expression. The prognoses of patients whose tumors expressed iNOS were significantly worse than those of patients whose tumors did not express iNOS. Multivariate analysis indicated iNOS expression was an independent prognostic factor.
CONCLUSION: iNOS might be associated with tumor progression by stimulating angiogenesis and suppressing immune responses in gastric carcinoma. (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020977     DOI: 10.1159/000086990

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

1.  Treatment of blood flow abnormality using mucosal delivery of nitric oxide.

Authors:  Chi H Lee
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

2.  Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein Barr associated gastric carcinomas.

Authors:  Maria D Begnami; Andre L Montagnini; Andre L Vettore; Sueli Nonogaki; Mariana Brait; Alex Y Simoes-Sato; Andrea Q A Seixas; Fernando A Soares
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

3.  Tumor cells upregulate normoxic HIF-1α in response to doxorubicin.

Authors:  Yiting Cao; Joseph M Eble; Ejung Moon; Hong Yuan; Douglas H Weitzel; Chelsea D Landon; Charleen Yu-Chih Nien; Gabi Hanna; Jeremy N Rich; James M Provenzale; Mark W Dewhirst
Journal:  Cancer Res       Date:  2013-08-19       Impact factor: 12.701

4.  Recruitment of dendritic cells in human liver with metastases.

Authors:  M Gulubova; I Manolova; G Cirovski; D Sivrev
Journal:  Clin Exp Metastasis       Date:  2008-06-27       Impact factor: 5.150

5.  Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.

Authors:  Jun Maeda; Masahiko Higashiyama; Akira Imaizumi; Tomio Nakayama; Hiroshi Yamamoto; Takashi Daimon; Minoru Yamakado; Fumio Imamura; Ken Kodama
Journal:  BMC Cancer       Date:  2010-12-22       Impact factor: 4.430

6.  Nos2 inactivation promotes the development of medulloblastoma in Ptch1(+/-) mice by deregulation of Gap43-dependent granule cell precursor migration.

Authors:  Daniel Haag; Petra Zipper; Viola Westrich; Daniela Karra; Karin Pfleger; Grischa Toedt; Frederik Blond; Nicolas Delhomme; Meinhard Hahn; Julia Reifenberger; Guido Reifenberger; Peter Lichter
Journal:  PLoS Genet       Date:  2012-03-15       Impact factor: 5.917

7.  Prognostic Value of Inducible Nitric Oxide Synthase (iNOS) in Human Cancer: A Systematic Review and Meta-Analysis.

Authors:  Wenbiao Liao; Tao Ye; Haoran Liu
Journal:  Biomed Res Int       Date:  2019-06-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.